Results 91 to 100 of about 737 (141)

Masthead: (View 3/2025)

VIEW, Volume 6, Issue 3, June 2025.
wiley   +1 more source

Antiviral effectiveness and survival correlation of azvudine and nirmatrelvir/ritonavir in elderly severe patients with COVID-19: a retrospective real-world studyResearch in context

EClinicalMedicine
Summary: Background: Azvudine and nirmatrelvir/ritonavir are approved to treat mild-to-moderate coronavirus disease 2019 (COVID-19) in adults with a high risk for progression to severe infection.
Shuxia Wang, Jin Sun, Xin Zhang, Man Li, Bangguo Qin, Miao Liu, Nan Zhang, Shengshu Wang, Tingyu Zhou, Wei Zhang, Cong Ma, Xinli Deng, Yongyi Bai, Geping Qu, Lin Liu, Hui Shi, Bo Zhou, Ke Li, Bo Yang, Suxia Li, Fan Wang, Jinling Ma, Lu Zhang, Yajuan Wang, Li An, Wenhui Liu, Qing Chang, Ru Zhang, Xi Yin, Yang Yang, Qiangguo Ao, Qiang Ma, Shuangtong Yan, Haili Huang, Peng Song, Linggen Gao, Wenning Lu, Lining Xu, Li Lei, Keyu Wang, Qi Zhang, Qing Song, Zhijian Zhang, Xiangqun Fang, Yao He, Tianzhi Li, Ping Zhu   +46 more
doaj   +1 more source

Selectively T cell phosphorylation activation of azvudine in the thymus tissue with immune protection effect

Acta Pharmaceutica Sinica B
Thymus is the important immune organ, responsible for T cell development and differentiation. The lower circulating T counts have been observed in patients who died from COVID-19 compared with survivors. Azvudine, also known as FNC, is a thymus-homing anti-SARS-CoV-2 drug in treating COVID-19 patients.
Ning Sheng, Rui Li, Yang Li, Zhe Wang, Lulu Wang, Yuhuan Li, Jinlan Zhang, Jiandong Jiang   +7 more
openaire   +3 more sources

Masthead: (View 2/2025)

VIEW, Volume 6, Issue 2, April 2025.
wiley   +1 more source

In vitro comparison of the susceptibilities of the same drug resistance mutations to reverse-transcriptase inhibitors of subtype B and CRF01_AE HIV-1 strains [PDF]

As the recommended drugs for first-line regimens in HIV-1 infections, reverse-transcriptase inhibitors (RTIs) are widely used around the world. To escape from the selective pressure imposed by RTIs, HIV-1 constantly mutates to adapt to its environment ...
Huimin Yan, Yongjian Liu, Jingwan Han, Lin Li, Kuiling Shen, Hanping Li, Lixuan Zhang, Bohan Zhang, Jingyun Li, Xiling Liu, Lei Jia, Erhei Dai, Xiaolin Wang   +12 more
core   +1 more source

Repurposing existing drugs for the treatment ofCOVID-19/SARS-CoV-2: A review of pharmacological effects and mechanism of action [PDF]

Following the coronavirus disease-2019 outbreak caused by severe acute respiratory syndrome coronavirus type 2 (SARS-CoV-2), there is an ongoing need to seek drugs that target COVID-19.
Peng Han, Shuchen Liu, Yunbo Sun, Yutong Liang, Xiaoxiao Quan, Zhuona Wu, Zhiyun Meng, Ruolan Gu, Guifang Dou, Hui Gan, Huajie Pan   +10 more
core   +1 more source

Identification of novel small-molecule inhibitors of SARS-CoV-2 by chemical genetics [PDF]

There are only eight approved small molecule antiviral drugs for treating COVID-19. Among them, four are nucleotide analogues (remdesivir, JT001, molnupiravir, and azvudine), while the other four are protease inhibitors (nirmatrelvir, ensitrelvir ...
Chan, Jasper Fuk Woo, Ge, Xing Yi, Guo, Qian, Chik, Kenn Ka Heng, Yuen, Kwok Yung, Wang, Tong Yun, Xie, Yubin, Cai, Jian Piao, Cui, Sheng, Huang, Yixin, Ni, Tao, Qin, Zhenzhi, Yuan, Shuofeng, Ye, Zi Wei, Dai, Mei, Ip, Jonathan Daniel, Tsang, Jessica Oi Ling, To, Kelvin Kai Wang, Chu, Allen Wing Ho, Chan, Wan Mui, Jin, Dong Yan, Wen, Lei, Chu, Hin, Tang, Kaiming, Ong, Chon Phin, Chan, Chris Chun Yiu, Qin, Bo, Cao, Jianli   +27 more
core   +1 more source

Antiviral effect of azvudine and nirmatrelvir-ritonavir among hospitalized patients with COVID-19

Journal of Infection, 2023
Yuan Gao, Zujin Luo, Shan Ren, Zhonghui Duan, Ying Han, Huihang Liu, Ziwen Gao, Xinyu Zhang, Zhongjie Hu, Yingmin Ma   +9 more
openaire   +2 more sources

Efficacy of Azvudine Therapy in Patients with Severe and Non-Severe COVID‐19: A Propensity Score-Matched Analysis

Infection and Drug Resistance
Siqin Zhang,1,* Songsong Tan,1,* Bin Yang,2 Yaoyao Wu,3 Guohang Yuan,3 Fengjiao Chen,4 Lin Liu3,5 1Department of Endocrinology and Metabolism, Guizhou Provincial People’s Hospital, Guiyang, Guizhou, 550002, People’s Republic of China; 2Department
Zhang S, Tan S, Yang B, Wu Y, Yuan G, Chen F, Liu L   +6 more
doaj  

The first Chinese oral anti-COVID-19 drug Azvudine launched

The Innovation, 2022
Bin Yu, Junbiao Chang
openaire   +2 more sources